ArticleCell transplantation2014
Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomes.
Article in Cell transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- A randomized controlled pilot trial of etanercept and alpha-1 antitrypsin to improve autologous islet engraftment.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2023Trial
- Challenges and opportunities in the islet transplantation microenvironment: a comprehensive summary of inflammatory cytokine, immune cells, and vascular endothelial cells.Frontiers in immunology · 2023Review
- Withaferin A inhibits lymphocyte proliferation, dendritic cell maturation in vitro and prolongs islet allograft survival.Scientific reports · 2021Article
- Extracellular HMGB1 exacerbates autoimmune progression and recurrence of type 1 diabetes by impairing regulatory T cell stability.Diabetologia · 2020Article
- The effect of preexisting HMGB1 within fetal bovine serum on murine pancreatic beta cell biology.Islets · 2020Article
- Pancreatic Islet Cell Transplantation: Graft Stability and Metabolic Outcomes.OBM transplantation · 2020Article
- Combined Analysis of GAD65, miR-375, and Unmethylated Insulin DNA Following Islet Transplantation in Patients With T1D.The Journal of clinical endocrinology and metabolism · 2019Article
- Islet cell autotransplantation update.CellR4-- repair, replacement, regeneration, & reprogramming · 2019Article
- Regulated Cell Death Seen through the Lens of Islet Transplantation.Cell transplantation · 2018Review
- The Spleen as an Optimal Site for Islet Transplantation and a Source of Mesenchymal Stem Cells.International journal of molecular sciences · 2018Review
- Early barriers to neonatal porcine islet engraftment in a dual transplant model.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2018Article
- Autoimmunity in Autologous Islet Transplantation.OBM transplantation · 2018Article
- Immunothrombotic Activity of Damage-Associated Molecular Patterns and Extracellular Vesicles in Secondary Organ Failure Induced by Trauma and Sterile Insults.Frontiers in immunology · 2018Review
- Role of High-Mobility Group Box 1 (HMGB1) in Transplantation of Rat Pancreatic Islets.Annals of transplantation · 2017Article
- Article
- Progress in Clinical Encapsulated Islet Xenotransplantation.Transplantation · 2016Review
- Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation.Frontiers in immunology · 2016Review
- The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes.Journal of diabetes research · 2016Review
- Monitoring Inflammation, Humoral and Cell-mediated Immunity in Pancreas and Islet Transplants.Current diabetes reviews · 2015Review
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
Abstract
A major problem after clinical autologous islet transplantation (AIT) is the difficulty in achieving insulin independence. To follow up on our demonstration in a murine model that high-mobility group box 1 (HMGB1) was released from islets and involved in early loss of transplanted islets, we tested the role of HMGB1 in clinical AIT. Serum HMGB1 levels from 15 AIT patients were significantly elevated during islet infusion (7.6 ± 1.2 ng/ml) and 24 h after infusion (8.0 ± 1.4 ng/ml) compared to admission levels (2.4 ± 0.6 ng/ml). The first elevation of HMGB1 was associated with islet damage, but the later elevation was not. The change in the HMGB1 level from admission to first peak (ΔHMGB1) was significantly higher in the AIT group (8.1 ± 1.1 ng/ml) than in the pancreatectomy-only control (2.2 ± 0.5 ng/ml) (p < 0.05). Circulating serum levels of soluble receptor for advanced glycation end products (sRAGE) were also elevated during islet infusion. In vitro studies demonstrated that damaged human islets released HMGB1 but not sRAGE. In terms of outcomes, the insulin-free group showed significantly lower ΔHMGB1 (5.2 ± 0.6 ng/ml) and higher ΔsRAGE (2.3 ± 0.6 ng/ml) than the insulin-dependent group (10.6 ± 1.9 ng/ml and 0.7 ± 0.2 ng/ml, respectively). The ΔHMGB1 correlated with the number of white blood cell, IP-10, EGF, and eotaxin. In conclusion, serum HMGB1 was elevated in AIT and could be associated with inflammatory reactions that deteriorate islet engraftment. Therefore, anti-HMGB1 therapy might be a candidate for further improving the outcomes of clinical AIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.